D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Duopharma Biotech Bhd
Accounts Receivables Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Accounts Receivables
myr227.5m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
19%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Accounts Receivables
myr31.6m
CAGR 3-Years
-11%
CAGR 5-Years
5%
CAGR 10-Years
6%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Accounts Receivables
myr194.4m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
6%
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Accounts Receivables
myr37.5m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Accounts Receivables
myr67.8m
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
4%
K
Kotra Industries Bhd
KLSE:KOTRA
Accounts Receivables
myr33.3m
CAGR 3-Years
14%
CAGR 5-Years
1%
CAGR 10-Years
-3%

See Also

What is Duopharma Biotech Bhd's Accounts Receivables?
Accounts Receivables
227.5m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Accounts Receivables amounts to 227.5m MYR.

What is Duopharma Biotech Bhd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
19%

Over the last year, the Accounts Receivables growth was 28%. The average annual Accounts Receivables growth rates for Duopharma Biotech Bhd have been 12% over the past three years , 5% over the past five years , and 19% over the past ten years .

Back to Top